More Than 17,800 Ice Cream Cartons Recalled Due to Plastic Contamination—Here's What to Know
The ice cream was sold in Texas, Iowa, Illinois, Wyoming, and Michigan.If you recently bought ice cream or frozen yogurt at the grocery store, check the label before consuming it. The U.S. Food and Drug Administration (FDA) announced a recall of more than 17,800 cartons of ice cream due to the presence of plastic pieces in the product.
The recall was initiated on April 25, 2025, by Wells Enterprises, Inc., based in Le Mars, Iowa. It includes 22 flavors of ice cream and frozen yogurt packaged in 3-gallon cartons. The recalled products were available at 103 centers nationwide, including Fort Worth, Texas; Houston, Texas; Le Mars, Iowa; Rosemont, Illinois; Wyoming; and Michigan.
On May 14, 2025, the FDA classified the recall as a Class II threat, which is "a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."
So far, no illnesses have been reported in connection with the recall. If you purchased the recalled products, do not eat them. Dispose of them immediately or return them to the place of purchase for a refund.
The affected products have "Best If Used By" dates from March 2026 through October 2025 printed on the packaging. Below is the full list of recalled products:
Rocky Road Flavored Ice Cream, 3 GAL, UPC: 070640050314, Item: 19695, LOT: 50009 HH 19115 18:00 510, "BEST IF USED BY" 10/10/26
Mocha Almond Fudge Ice Cream, 3 GAL, LOT: 50016 HH 19115 18:00 5100 "BEST IF USED BY" 10/09/26
Peanut Butter 'N Fudge Ice Cream, 3 GAL, UPC: 070640050574, Item: 33429, LOT: 50012 HH 19115 18:00 5098 "BEST IF USED BY" 10/07/26
Country Rich Vanilla Ice Cream, 3 GAL, UPC: 070640600052, Item: 102010, LOT: 50085 HH 19115 18:00 5108 "BEST IF USED BY" 10/17/26
Scooper Hero Ice Cream, 3 GAL, UPC: 070640050642, Item: 487054, LOT50011 HH 19115 18:00 5087 "BEST IF USED BY" 09/26/26
Cotton Candy Flavored Ice Cream, 3 GAL, UPC: 070640050482, Item: 662429, LOT: 50018 HH 19115 18:00 5099 "BEST IF USED BY" 10/08/26
GFGB Vanilla Bean Flavored Ice Cream, 3 GAL, UPC: 070640000272, Item: 669740, LOT: 50024 HH 19115 18:00 5093 "BEST IF USED BY" 4/3/26
Quick Blend Vanilla Flavored Ice Cream, 3 GAL, UPC: 070640050604, Item: 773034, LOT: 50034 HH 19115 18:00 5098 "BEST IF USED BY" 10/07/26
Planet Smoothie ZSA Vanilla Flavored Fat Free Frozen Yogurt, 3 GAL, UPC: 070640005567, Item: 889334, LOT: 50014 HH 19115 18:00 5091 "BEST IF USED BY" 04/01/26
Johnny Rockets Vanilla Flavored Ice Cream, 3 GAL, UPC: 070640006564, Item: 902486, LOT: 50029 HH 19115 18:00 5094 "BEST IF USED BY" 10/3/26
BIPC Flavored Ice Cream, 3 GAL, UPC: 070640008025, Item: 934085, LOT: 50024 HH 19115 18:00 5105 "BEST IF USED BY" OCT/14/26
Vanilla Frozen Yogurt, 3 GAL, UPC: 00070640022144, Item: 1352604, LOT: 50002HH 19115 18:00 5091 "BEST IF USED BY" 9/30/26
Vanilla Flavored Ice Cream, 3 GAL, UPC: 070640022250, Item: 1355358, LOT: 50005 HH 19115 18:00 5097 "BEST IF USED BY" 10/06/26
GFGB 12% Vanilla Flavored Ice Cream, 3 GAL, UPC: 070640018451, Item: 1435313, LOT: 50004 HH 19115 18:00 5092 "BEST IF USED BY" 4/2/26
Gordon Choice Vanilla Flavored Ice Cream, 3 GAL, UPC: 00093901820730, Item: 1367499, LOT: 50003 HH 19115 18:00 5093 "BEST IF USED BY" 10/02/26
Vanilla Bean Ice Cream with Madagascar vanilla, 3 GAL, UPC: 50758108658085, Item: 945313, LOT: 50026 HH 19115 18:00 5094 "BEST IF USED BY" 10/3/26
Glenview Farms Vanilla Flavored Ice Cream, 3 GAL, UPC: 50758108118398, Item: 785848, LOT: 50066HH 19115 18:00 5105 "BEST IF USED BY" 10/14/26
Glenview Farms Chocolate Ice Cream, 3 GAL, UPC: 50758108118404, Item: 785855, LOT: 50033HH 19115 18:00 5101 "BEST IF USED BY" 10/10/26
Glenview Farms Artificially Flavored French Vanilla Ice Cream, 3 GAL, UPC: 50758108392668, Item: 785887, LOT: 50015HH 19115 18:00 5094 "BEST IF USED BY" 10/3/26
Artificially Flavored French Vanilla Ice Cream, 3 GAL, UPC: 00074865257275, Item: 1026416, LOT: 50025 HH 19115 18:00 5087 "BEST IF USED BY" 3/28/26
Keith Valley Vanilla Flavored Ice Cream, 3 GAL, UPC: 046045065871, Item: 1144343, LOT: 50004HH 19115 18:00 5100 "BEST IF USED BY" 10/9/26
Ellington Farms Vanilla Flavored Ice Cream, 3 GAL, UPC: 046045065833, Item: 1144464, LOT: 50003HH 19115 18:00 5087 "BEST IF USED BY" 9/26/26
Read the original article on Martha Stewart
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity. The accelerated approval is based on part 1 of the ESSENCE trial, in which Wegovy® demonstrated a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo. The clinical data from ESSENCE showed that at week 72, 36.8% of people treated with Wegovy® achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.4% treated with placebo. 62.9% of people treated with Wegovy® achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.3% treated with placebo. 'Wegovy® is now uniquely positioned as the first and only GLP-1 treatment approved for MASH, complementing the already proven weight loss, cardiovascular benefits and extensive body of evidence linked to semaglutide,' said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development, at Novo Nordisk. 'MASH represents a significant health burden, with one in three people with overweight or obesity worldwide affected. In the US alone, around 22 million people are estimated to live with MASH. With the approval of Wegovy® for MASH, we provide a new treatment to people living with MASH that not only halts the disease activity but helps reverse the damage caused to the liver.' As of today, Wegovy® is available in the US for the treatment for MASH. About MASH Metabolic dysfunction-associated steatohepatitis (MASH) is a serious, progressive, metabolic disease affecting the liver, which can be fatal if not properly managed. More than 250 million people live with MASH and the number of individuals in advanced stages of the disease is expected to double by 2030. Of those who are currently overweight or living with obesity, more than one in three are also living with MASH. People living with MASH often experience few or no specific symptoms in the early stages of the disease, which often results in delayed diagnosis. The risk of progression to advanced liver disease, including liver cancer, is higher in people living with MASH than in the general population. About the ESSENCE trial ESSENCE is a phase 3 trial evaluating the effect of once-weekly subcutaneous semaglutide 2.4 mg in adults with metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis (stage 2 or 3). ESSENCE is a two-part trial where 1,200 planned participants were randomised 2:1 to receive semaglutide 2.4 mg or placebo, on top of standard of care for 240 weeks. In part 1, the objective was to demonstrate that treatment with semaglutide 2.4 mg improves liver histology at 72 weeks based on biopsy sampling from the first 800 randomised patients. In part 2, the objective is to demonstrate that treatment with semaglutide 2.4 mg lowers the risk of liver-related clinical events compared to placebo in adults with MASH and moderate to advanced liver fibrosis at 240 weeks. Based on part 1 of the ESSENCE trial, Novo Nordisk has also filed for regulatory approval in the EU in February 2025, with a subsequent filing in Japan in May 2025. Part 2 of the ESSENCE trial is expected to read out in 2029. About Wegovy® (semaglutide 2.4 mg) The FDA initially approved Wegovy® in 2021 with a reduced calorie meal plan and increased physical activity to help adults with obesity, or adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off. The indication was expanded in 2022 to include children aged 12 years and older with obesity. In 2024, Wegovy® was approved to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and either obesity or overweight. Today, the FDA granted accelerated approval for Wegovy® for a new patient population for the treatment of MASH in adults with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information: Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode +45 3075 5956 jrde@ Sina Meyer +45 3079 6656 azey@ Frederik Taylor Pitter (US) +1 609 613 0568 fptr@ Max Ung +45 3077 6414 mxun@ Publication of inside information pursuant to Market Abuse Regulation, Article 17. Attachment CA250815-MASH-US-label-update
Fast Company
an hour ago
- Fast Company
America's first needle-free, at-home flu vaccine is now available
There's one less excuse to skip the flu shot this season. Pharmaceutical company AstraZeneca is out with a new version of the flu vaccine, and it makes getting vaccinated easier than ever. The drug can be administered at home, giving you one less reason to trek to the doctor's office. And even better for the needle-averse: You don't need a jab to get it – the vaccine comes in nasal spray form. The drug, which was approved by the FDA last fall, is available now and can be ordered online. While it will cost $70 out of pocket, AstraZeneca says that anyone with insurance coverage will only need to pay $8.99 for shipping. FluMist Home ships in a special cooling container and does need to be stored in a cool environment, so if you order it pop it in your fridge until you plan to administer the vaccine. Flu vaccination rates are on the downswing in the U.S., a phenomenon linked to pandemic fatigue and vaccine misinformatio n. While the flu is an endemic virus that comes back around every year, it can still be dangerous for unimmunized kids, older adults, and people with compromised immune systems. The flu vaccine isn't the only shot that Americans are skipping. From 2019 to 2023, measles vaccination rates fell from 95% to 92%, dipping below the critical threshold for population-level protection. Anti-vaccine activism is rising in the U.S. and that movement now has Robert F. Kennedy Jr., a prominent ally, running the Department of Health and Human Services. On Thursday, HHS announced that it will bring back a task force aimed at scrutinizing the safety of vaccines for children. The Children's Health Defense, an anti-vaccine group founded by Kennedy, called for the task force to be reestablished in a lawsuit against its former leader filed in May.
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
Nasal spray flu vaccine can now be shipped to your home. Here's how to get it
The first nasal spray flu vaccine, FluMist, can now be shipped to your home. FluMist, made by the drug company AstraZeneca, has been approved in the United States since 2003, but its use was limited to health care settings like hospitals and flu clinics. In 2024, the FDA approved it for at-home administration, making it the first nasal spray vaccine approved for widespread use at home. On Friday, AstraZeneca announced a home delivery service for the product, which infectious disease experts hope will lead to more people getting vaccinated against seasonal influenza. The service is available in 34 states including California, for the upcoming 2025-26 flu season. Prior to the approval for at-home use, FluMust had been given mostly in pediatricians' offices because many children have a fear of needles. As many as 2 in 3 children and 1 in 4 adults have a strong fear of needles, according to CDC estimates. Here's what you need to know about the nasal spray vaccine: It's approved for people aged 2 to 49 Adults can self-administer it; it's given through two sprays, one in each nostril. Children should get it administered by a parent or caregiver. You need a prescription Adults can go to to order the vaccine and will be asked to complete a medical screening questionnaire, AstraZeneca said. A licensed health care provider will review the submission to determine eligibility. Once eligibility is confirmed and insurance is verified, the vaccine will be prescribed and shipped directly to consumers' home on the date they selected. It will come with instructions on how to administer, store and dispose the product. Cost Cost will depend on individuals' insurance, but most insurance plans cover flu vaccines at no cost. There is a $8.99 shipping and processing fee per order. It may not be for everyone Anyone who is wheezing, has asthma, has Guillain-Barre syndrome, has a weakened immune system or has problems with the heart, kidneys or lung should check with their health care provider before getting FluMust, according to AstraZeneca. People who are pregnant or nursing, or who have diabetes, should also check with their doctor first. Children under 5 with a history of wheezing should also check with their doctor. Children and adolescents up to 17 years old who are taking aspirin or medicines containing aspirin should not get FluMust. Side effects The most common side effects are runny or stuffy nose, sore throat and fever over 100 degrees.
